Kairos Pharma announces positive safety results from Phase 2 ENV-105 trial

Kairos Pharma (KAPA) announced positive safety results from its ongoing Phase 2 clinical trial of ENV-105 in patients with metastatic castration-resistant prostate cancer. The interim safety analysis of the first 10 enrolled patients demonstrated that ENV-105 was well tolerated when combined with standard-of-care hormone therapy, apalutamide. To date, no dose-limiting toxicities, unexpected adverse events, or Grade 3 or 4 toxicities were observed. Interim efficacy data from the trial are expected to be reported in September 2025.